Loading...

Adil Daud, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentMedicine
Address1600 Divisadero
San Francisco CA 94115
Phone415-353-7392
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Featured Presentations
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Twitter
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. PMID: 28822576.
      View in: PubMed
    2. Loo K, Tsai KK, Mahuron K, Liu J, Pauli ML, Sandoval PM, Nosrati A, Lee J, Chen L, Hwang J, Levine LS, Krummel MF, Algazi AP, Alvarado MD, Rosenblum MD, Daud A. Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight. 2017 Jul 20; 2(14). PMID: 28724802.
      View in: PubMed
    3. Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2017 Jul 03; JCO2016718023. PMID: 28671856.
      View in: PubMed
    4. Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017 Jun 01; 28(6):1380-1387. PMID: 28327988.
      View in: PubMed
    5. Daud A, Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017 May 18. PMID: 28526719.
      View in: PubMed
    6. Nosrati A, Tsai KK, Goldinger SM, Tumeh P, Grimes B, Loo K, Algazi AP, Nguyen-Kim TD, Levesque M, Dummer R, Hamid O, Daud A. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy. Br J Cancer. 2017 Mar 21. PMID: 28324889.
      View in: PubMed
    7. Daud A, Kluger HM, Kurzrock R, Schimmoller F, Weitzman AL, Samuel TA, Moussa AH, Gordon MS, Shapiro GI. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer. 2017 Feb 14; 116(4):432-440. PMID: 28103611.
      View in: PubMed
    8. Daud A, Gill J, Kamra S, Chen L, Ahuja A. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol. 2017 Jan 04; 10(1):3. PMID: 28052762.
      View in: PubMed
    9. Loo K, Daud A. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs. Cancer J. 2017 Jan/Feb; 23(1):3-9. PMID: 28114249.
      View in: PubMed
    10. Daud A, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, Joshua AM, Kefford R, Hersey P, Joseph R, Gangadhar TC, Dronca R, Patnaik A, Zarour H, Roach C, Toland G, Lunceford JK, Li XN, Emancipator K, Dolled-Filhart M, Kang SP, Ebbinghaus S, Hamid O. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016 Dec; 34(34):4102-4109. PMID: 27863197.
      View in: PubMed
    11. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung BM, Pincus L, Daud A. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016; 4:58. PMID: 27660712.
      View in: PubMed
    12. Daud A, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai K, Nosrati A, Nardo L, Alvarado MD, Algazi AP, Pampaloni MH, Lobach IV, Hwang J, Pierce RH, Gratz IK, Krummel MF, Rosenblum MD, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016 Aug 15. PMID: 27525433.
      View in: PubMed
    13. Yap LB, Nguyen ST, Qadir F, Ma SK, Muhammad Z, Koh KW, Ali Z, Tay GS, Daud A, Said A, Sahat N, Rebo R, Tamin SS, Hussin A, Kaur S, Omar R. A comparison of long-term outcomes between narrow and broad QRS complex patients treated with cardiac resynchronization therapy. Acta Cardiol. 2016 Jun; 71(3):323-30. PMID: 27594128.
      View in: PubMed
    14. Daud A. Part I: Checkpoint inhibitors in cancer therapy. Immunotherapy. 2016 Jun; 8(6):675-6. PMID: 27197535.
      View in: PubMed
    15. Daud A. Part II: Checkpoint inhibitors in cancer therapy. Immunotherapy. 2016 Jun; 8(7):761-2. PMID: 27349974.
      View in: PubMed
    16. Chen L, Daud A. A Review of Novel Intralesional Therapies for Melanoma, With an Emphasis on a Potential Combination Approach. Oncology (Williston Park). 2016 May; 30(5). PMID: 27188675.
      View in: PubMed
    17. Daud A, Nandoskar P. Pembrolizumab for melanoma- safety profile and future trends. Expert Opin Drug Saf. 2016 Jun; 15(6):727-9. PMID: 27056241.
      View in: PubMed
    18. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016 Jun 30; 374(26):2542-52. PMID: 27093365.
      View in: PubMed
    19. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9. PMID: 27092830.
      View in: PubMed
    20. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. J Clin Oncol. 2016 May 1; 34(13):1510-7. PMID: 26951310.
      View in: PubMed
    21. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 May; 27(5):947-52. PMID: 26903311.
      View in: PubMed
    22. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8. PMID: 26811525.
      View in: PubMed
    23. McElroy LM, Woods DM, Yanes AF, Skaro AI, Daud A, Curtis T, Wymore E, Holl JL, Abecassis MM, Ladner DP. Applying the WHO conceptual framework for the International Classification for Patient Safety to a surgical population. Int J Qual Health Care. 2016 Apr; 28(2):166-74. PMID: 26803539.
      View in: PubMed
    24. Garrett GL, He SY, Sabouni N, Daud A, Arron ST. Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. JAAD Case Rep. 2015 Nov; 1(6):S23-5. PMID: 27051803.
      View in: PubMed
    25. Tsai KK, Daud A. Nivolumab plus ipilimumab in the treatment of advanced melanoma. J Hematol Oncol. 2015; 8(1):123. PMID: 26518223; PMCID: PMC4628394.
      View in: PubMed, PubMed Central
    26. Daud A. Current and Emerging Perspectives on Immunotherapy for Melanoma. Semin Oncol. 2015 Dec; 42 Suppl 3:S3-S11. PMID: 26598057.
      View in: PubMed
    27. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 1; 33(34):4023-31. PMID: 26392102.
      View in: PubMed
    28. Zia Y, Chen L, Daud A. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. Expert Opin Pharmacother. 2015; 16(14):2257-63. PMID: 26331795.
      View in: PubMed
    29. Middleton MR, Friedlander P, Hamid O, Daud A, Plummer R, Falotico N, Chyla B, Jiang F, McKeegan E, Mostafa NM, Zhu M, Qian J, McKee M, Luo Y, Giranda VL, McArthur GA. Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. Ann Oncol. 2015 Oct; 26(10):2173-9. PMID: 26202595.
      View in: PubMed
    30. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18. PMID: 26115796.
      View in: PubMed
    31. Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW. Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Oct 1; 21(19):4286-93. PMID: 25977344.
      View in: PubMed
    32. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015 Jun 25; 372(26):2521-32. PMID: 25891173.
      View in: PubMed
    33. Tsai KK, Daud A. The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015 Apr; 75(6):563-75. PMID: 25802230.
      View in: PubMed
    34. Algazi AP, Cha E, Ortiz-Urda SM, McCalmont T, Bastian BC, Hwang J, Pampaloni MH, Behr S, Chong K, Cortez B, Quiroz A, Coakley F, Liu S, Daud A. The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer. 2015 Apr 14; 112(8):1326-31. PMID: 25867272; PMCID: PMC4402449 [Available on 04/14/16].
      View in: PubMed, PubMed Central
    35. Daud A, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar 20; 33(9):1060-6. PMID: 25605849.
      View in: PubMed
    36. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. Cancer Cell. 2014 Dec 08; 26(6):938. PMID: 28898680.
      View in: PubMed
    37. Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, Aktan G, Ouellet D, Jin F, Long GV, Daud A. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Ann Oncol. 2015 Feb; 26(2):415-21. PMID: 25411413.
      View in: PubMed
    38. Chen FW, Tseng D, Reddy S, Daud A, Swetter SM. Involution of eruptive melanocytic nevi on combination BRAF and MEK inhibitor therapy. JAMA Dermatol. 2014 Nov; 150(11):1209-12. PMID: 25142409.
      View in: PubMed
    39. Sanlorenzo M, Choudhry A, Vujic I, Posch C, Chong K, Johnston K, Meier M, Osella-Abate S, Quaglino P, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014 Dec; 71(6):1102-1109.e1. PMID: 25440439; PMCID: PMC4254519 [Available on 12/01/15].
      View in: PubMed, PubMed Central
    40. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM, Krummel MF. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014 Nov 10; 26(5):638-52. PMID: 25446897; PMCID: PMC4254577.
      View in: PubMed, PubMed Central
    41. Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, Falchook GS, Algazi A, Lewis K, Long GV, Patel K, Ibrahim N, Sun P, Little S, Cunningham E, Sosman JA, Daud A, Gonzalez R. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704. PMID: 25287827; PMCID: PMC4226803 [Available on 11/20/15].
      View in: PubMed, PubMed Central
    42. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K, Kee D, Boasberg P, Yin M, Chan I, Musib L, Choong N, Puzanov I, McArthur GA. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65. PMID: 25037139.
      View in: PubMed
    43. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, Joseph RW, Boasberg P, Chmielowski B, Mateus C, Postow MA, Gergich K, Elassaiss-Schaap J, Li XN, Iannone R, Ebbinghaus SW, Kang SP, Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17. PMID: 25034862.
      View in: PubMed
    44. Ashworth MT, Daud A. Combinatorial approach to treatment of melanoma. Hematol Oncol Clin North Am. 2014 Jun; 28(3):601-12. PMID: 24880950.
      View in: PubMed
    45. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, Dimaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014 May; 12(5):621-9. PMID: 24812131.
      View in: PubMed
    46. Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A, Osella-Abate S, Quaglino P, Daud A, Ortiz-Urda S. Melanoma immunotherapy. Cancer Biol Ther. 2014 Jun 1; 15(6):665-74. PMID: 24651672; PMCID: PMC4049781.
      View in: PubMed, PubMed Central
    47. Ashworth MT, Daud A. Management of a patient with advanced BRAF-mutant melanoma. J Natl Compr Canc Netw. 2014 Mar 1; 12(3):315-9; quiz 319. PMID: 24616537.
      View in: PubMed
    48. Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. PMID: 24374975.
      View in: PubMed
    49. Tsai KK, Zarzoso I, Daud A. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother. 2014; 10(11):3111-6. PMID: 25625924; PMCID: PMC4514131 [Available on 01/27/16].
      View in: PubMed, PubMed Central
    50. Grippo JF, Zhang W, Heinzmann D, Yang KH, Wong J, Joe AK, Munster P, Sarapa N, Daud A. A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma. Cancer Chemother Pharmacol. 2014 Jan; 73(1):103-11. PMID: 24178368.
      View in: PubMed
    51. Daud A. Reply to M.-E. Percival et al and L.B. Saltz. J Clin Oncol. 2013 Jul 1; 31(19):2515-6. PMID: 23967490.
      View in: PubMed
    52. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013 Jul 11; 369(2):134-44. PMID: 23724846; PMCID: PMC4126516.
      View in: PubMed, PubMed Central
    53. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dimaio D, Fleming MD, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM, McMillian N, Ho M. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Apr 1; 11(4):395-407. PMID: 23584343.
      View in: PubMed
    54. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud A, McCalmont TH, LeBoit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 5; 110(10):4015-20. PMID: 23431193; PMCID: PMC3593920.
      View in: PubMed, PubMed Central
    55. Daud A. Removing the unknown from the carcinoma of unknown primary. J Clin Oncol. 2013 Jan 10; 31(2):174-5. PMID: 23233703.
      View in: PubMed
    56. Cha E, Daud A. Plasmid IL-12 electroporation in melanoma. Hum Vaccin Immunother. 2012 Nov 1; 8(11):1734-8. PMID: 23151447; PMCID: PMC3601150.
      View in: PubMed, PubMed Central
    57. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov; 367(18):1694-703. PMID: 23020132; PMCID: PMC3549295.
      View in: PubMed, PubMed Central
    58. Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther. 2012 Aug; 12(8):1087-99. PMID: 22694288.
      View in: PubMed
    59. Chong K, Daud A, Ortiz-Urda S, Arron ST. Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg. 2012 Jun; 31(2):140-9. PMID: 22640435; PMCID: PMC3367308.
      View in: PubMed, PubMed Central
    60. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc Netw. 2012 Mar; 10(3):366-400. PMID: 22393197.
      View in: PubMed
    61. Daud A, Bastian BC. Beyond BRAF in melanoma. Curr Top Microbiol Immunol. 2012; 355:99-117. PMID: 21826607.
      View in: PubMed
    62. Daud A, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012 Feb 15; 18(4):1092-100. PMID: 22179664.
      View in: PubMed
    63. Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud A. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Jan 3; 106(1):85-91. PMID: 22127285; PMCID: PMC3251861.
      View in: PubMed, PubMed Central
    64. Daud A. BEAM trial: lighting the way ahead? J Clin Oncol. 2012 Jan 1; 30(1):6-7. PMID: 22124100.
      View in: PubMed
    65. Munster PN, Daud A. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs. 2011 Nov; 20(11):1565-74. PMID: 21985236.
      View in: PubMed
    66. Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud A, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15; 17(24):7765-75. PMID: 21994418; PMCID: PMC3972922.
      View in: PubMed, PubMed Central
    67. Ahronowitz IZ, Daud A, Leong SP, Shue EH, Bastian BC, McCalmont TH, Yu SS. An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. J Cutan Pathol. 2011 Oct; 38(10):801-7. PMID: 21883364.
      View in: PubMed
    68. Soon CW, Algazi AP, Cha EN, Webb EM, Daud A. NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol. 2011 May; 147(5):626-7. PMID: 21576590.
      View in: PubMed
    69. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M. Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol. 2011 May 1; 103(6):538-49. PMID: 21480247.
      View in: PubMed
    70. Chow H, Jung A, Talbott J, Lin AM, Daud A, Coakley FV. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90. PMID: 21245693; PMCID: PMC3675219.
      View in: PubMed, PubMed Central
    71. DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud A. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer. 2010 Nov 9; 103(10):1548-53. PMID: 20924376; PMCID: PMC2990578.
      View in: PubMed, PubMed Central
    72. Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010 Oct; 33(8):817-27. PMID: 20842055.
      View in: PubMed
    73. Algazi AP, Soon CW, Daud A. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010; 2:197-211. PMID: 21188111; PMCID: PMC3004577.
      View in: PubMed, PubMed Central
    74. Daud A, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon a-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Mar; 67(3):657-66. PMID: 20509027; PMCID: PMC3043235.
      View in: PubMed, PubMed Central
    75. Soon CW, Algazi AP, Cha EN, Daud A. New horizons in melanoma treatment: targeting molecular pathways. Ochsner J. 2010; 10(2):93-8. PMID: 21603363; PMCID: PMC3096197.
      View in: PubMed, PubMed Central
    76. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 6; 101(7):1044-50. PMID: 19738609; PMCID: PMC2768109.
      View in: PubMed, PubMed Central
    77. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud A. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res. 2009 Jun; 19(3):167-75. PMID: 19434004.
      View in: PubMed
    78. Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009 Jun 10; 27(17):2823-30. PMID: 19349552.
      View in: PubMed
    79. Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009 Apr 1; 15(7):2488-96. PMID: 19318486.
      View in: PubMed
    80. Daud A, Dawson J, DeConti RC, Bicaku E, Marchion D, Bastien S, Hausheer FA, Lush R, Neuger A, Sullivan DM, Munster PN. Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial. Clin Cancer Res. 2009 Apr 1; 15(7):2479-87. PMID: 19318485.
      View in: PubMed
    81. Solit DB, Osman I, Polsky D, Panageas KS, Daud A, Goydos JS, Teitcher J, Wolchok JD, Germino FJ, Krown SE, Coit D, Rosen N, Chapman PB. Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res. 2008 Dec 15; 14(24):8302-7. PMID: 19088048; PMCID: PMC2629404.
      View in: PubMed, PubMed Central
    82. Daud A, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec 20; 26(36):5896-903. PMID: 19029422; PMCID: PMC2645111.
      View in: PubMed, PubMed Central
    83. Demierre MF, Sabel MS, Margolin KA, Daud A, Sondak VK. State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer. 2008 Oct 1; 113(7 Suppl):1728-43. PMID: 18798543.
      View in: PubMed
    84. Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud A, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008 Nov 10; 26(32):5198-203. PMID: 18824702.
      View in: PubMed
    85. Verschraegen CF, Skubitz K, Daud A, Kudelka AP, Rabinowitz I, Allievi C, Eisenfeld A, Singer JW, Oldham FB. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2009 Apr; 63(5):903-10. PMID: 18682950.
      View in: PubMed
    86. Zager JS, Daud A. Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios. Cancer Control. 2008 Jul; 15(3):192-4. PMID: 18596670.
      View in: PubMed
    87. Messina JL, Yu H, Riker AI, Munster PN, Jove RL, Daud A. Activated stat-3 in melanoma. Cancer Control. 2008 Jul; 15(3):196-201. PMID: 18596671.
      View in: PubMed
    88. Daud A, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, Deconti RC, Gabrilovich D. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008 Jul 1; 26(19):3235-41. PMID: 18591558.
      View in: PubMed
    89. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008; 1:13. PMID: 18442402; PMCID: PMC2408576.
      View in: PubMed, PubMed Central
    90. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud A. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct 1; 13(19):5855-61. PMID: 17908979.
      View in: PubMed
    91. Homsi J, Daud A. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control. 2007 Jul; 14(3):285-94. PMID: 17615535.
      View in: PubMed
    92. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May 20; 25(15):1979-85. PMID: 17513804.
      View in: PubMed
    93. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007 Jan; 11(1):91-100. PMID: 17150037.
      View in: PubMed
    94. Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Ann Surg Oncol. 2007 Apr; 14(4):1416-23. PMID: 17195911.
      View in: PubMed
    95. Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ. Melanoma. J Natl Compr Canc Netw. 2006 Aug; 4(7):666-84. PMID: 16884669.
      View in: PubMed
    96. Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 1; 12(15):4645-51. PMID: 16899614.
      View in: PubMed
    97. Lew JI, Daud A, DiGorgi MF, Olivero-Rivera L, Davis DG, Bessler M. Preoperative esophageal manometry and outcome of laparoscopic adjustable silicone gastric banding. Surg Endosc. 2006 Aug; 20(8):1242-7. PMID: 16858533.
      View in: PubMed
    98. Schrope BA, Daud A, Bessler M. Unintentional creation of reverse peristaltic alimentary limb during Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis. 2006 Jul-Aug; 2(4):478-82. PMID: 16925386.
      View in: PubMed
    99. Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud A. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul; 13(3):211-7. PMID: 16885917.
      View in: PubMed
    100. Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A, Heller R. Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin Cancer Res. 2006 May 15; 12(10):3177-83. PMID: 16707618.
      View in: PubMed
    101. Riker AI, Jove R, Daud A. Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci. 2006; 11:1-14. PMID: 16146709.
      View in: PubMed
    102. Kim TH, Daud A, Ude AO, DiGiorgi M, Olivero-Rivera L, Schrope B, Davis D, Inabnet WB, Bessler M. Early U.S. outcomes of laparoscopic gastric bypass versus laparoscopic adjustable silicone gastric banding for morbid obesity. Surg Endosc. 2006 Feb; 20(2):202-9. PMID: 16341569.
      View in: PubMed
    103. Marchion DC, Bicaku E, Daud A, Sullivan DM, Munster PN. In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther. 2005 Dec; 4(12):1993-2000. PMID: 16373714.
      View in: PubMed
    104. Marchion DC, Bicaku E, Turner JG, Daud A, Sullivan DM, Munster PN. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res. 2005 Dec 1; 11(23):8467-75. PMID: 16322310.
      View in: PubMed
    105. Homsi J, Kashani-Sabet M, Messina JL, Daud A. Cutaneous melanoma: prognostic factors. Cancer Control. 2005 Oct; 12(4):223-9. PMID: 16258493.
      View in: PubMed
    106. Marchion DC, Bicaku E, Daud A, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res. 2005 May 1; 65(9):3815-22. PMID: 15867379.
      View in: PubMed
    107. Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study. Clin Cancer Res. 2005 Apr 15; 11(8):3009-16. PMID: 15837755.
      View in: PubMed
    108. Naing A, Messina JL, Vrionis FR, Daud A. Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol. 2004 Aug 1; 22(15):3194-5. PMID: 15284274.
      View in: PubMed
    109. Marchion DC, Bicaku E, Daud A, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem. 2004 May 15; 92(2):223-37. PMID: 15108350.
      View in: PubMed
    110. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002 Oct 10; 21(46):7001-10. PMID: 12370822.
      View in: PubMed
    111. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002 Aug; 8(8):2505-11. PMID: 12171876.
      View in: PubMed
    112. Daud A, Munster P, Munster P, Spriggs DR. New drugs in gynecologic cancer. Curr Treat Options Oncol. 2001 Apr; 2(2):119-28. PMID: 12057130.
      View in: PubMed
    113. Din J, Qureshi A, Daud A, Ahmad H. Intrahepatic stones: the UKM experience. Med J Malaysia. 2000 Dec; 55(4):473-7. PMID: 11221160.
      View in: PubMed
    114. Klöckner U, Lee JH, Cribbs LL, Daud A, Hescheler J, Pereverzev A, Perez-Reyes E, Schneider T. Comparison of the Ca2 + currents induced by expression of three cloned alpha1 subunits, alpha1G, alpha1H and alpha1I, of low-voltage-activated T-type Ca2 + channels. Eur J Neurosci. 1999 Dec; 11(12):4171-8. PMID: 10594642.
      View in: PubMed
    115. Talley EM, Cribbs LL, Lee JH, Daud A, Perez-Reyes E, Bayliss DA. Differential distribution of three members of a gene family encoding low voltage-activated (T-type) calcium channels. J Neurosci. 1999 Mar 15; 19(6):1895-911. PMID: 10066243.
      View in: PubMed
    116. Cribbs LL, Lee JH, Yang J, Satin J, Zhang Y, Daud A, Barclay J, Williamson MP, Fox M, Rees M, Perez-Reyes E. Cloning and characterization of alpha1H from human heart, a member of the T-type Ca2+ channel gene family. Circ Res. 1998 Jul 13; 83(1):103-9. PMID: 9670923.
      View in: PubMed
    117. Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay J, Williamson MP, Fox M, Rees M, Lee JH. Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature. 1998 Feb 26; 391(6670):896-900. PMID: 9495342.
      View in: PubMed
    118. Kim KK, Soonpaa MH, Daud A, Koh GY, Kim JS, Field LJ. Tumor suppressor gene expression during normal and pathologic myocardial growth. J Biol Chem. 1994 Sep 9; 269(36):22607-13. PMID: 8077211.
      View in: PubMed
    119. Daud A, Bumpus FM, Husain A. Characterization of angiotensin I-converting enzyme (ACE)-containing follicles in the rat ovary during the estrous cycle and effects of ACE inhibitor on ovulation. Endocrinology. 1990 Jun; 126(6):2927-35. PMID: 2161740.
      View in: PubMed
    Adil's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (426) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (30) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    Back to TOP